Shubham Pant
M.D. Anderson Cancer Center · Academic and Community Cancer Research United · University of Oklahoma
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shubham Pant as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05497778 · A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.M.D. Anderson Cancer Center · active not recruiting · Pancreas Cancer · principal investigator
- Ph1NCT04132505 · Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic CancerM.D. Anderson Cancer Center · completed · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- Ph1NCT04088188 · Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaAcademic and Community Cancer Research United · terminated · Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma · principal investigator
- Ph1/Ph2NCT03637803 · Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors4D pharma plc · terminated · Oncology, Solid Tumor, Non Small Cell Lung Cancer · principal investigator
- Ph1NCT03616574 · First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid TumorsHoly Stone Healthcare Co., Ltd · completed · Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC) · principal investigator
- Ph2NCT01359007 · FOLFIRINOX in Patients With Inoperable Pancreatic CancerUniversity of Oklahoma · terminated · Adenocarcinoma of Pancreas · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2023 · $392,596 awarded in 2023Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT04088188
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 91 PubMed records, and a shared surname and initials can bring in a namesake. All 91 on PubMed
- 458 citationsRCR 44.1
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh.Lancet Glob Health · 2021256 citationsRCR 22.4
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.Lancet Oncol · 2023248 citationsRCR 20.9
- Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.Nat Med · 2024243 citationsRCR 26.9
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.Lancet Oncol · 2023204 citationsRCR 16.4
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.J Clin Oncol · 2016186 citationsRCR 5.2
- 175 citationsRCR 10.9
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.Mol Ther · 2016135 citationsRCR 3.9
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.J Immunother Cancer · 2019131 citationsRCR 5.2